Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th

Onconetix, Inc. (NASDAQ:ONCOFree Report)’s stock is going to reverse split on Tuesday, September 24th. The 1-40 reverse split was announced on Friday, September 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 23rd.

Onconetix Stock Down 28.7 %

Shares of ONCO stock opened at $0.08 on Friday. The stock has a fifty day moving average price of $0.14 and a 200 day moving average price of $0.15. The company has a quick ratio of 0.09, a current ratio of 0.10 and a debt-to-equity ratio of 0.08. Onconetix has a 1 year low of $0.08 and a 1 year high of $0.62.

Onconetix (NASDAQ:ONCOGet Free Report) last announced its quarterly earnings results on Thursday, August 29th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.71 million during the quarter.

Institutional Trading of Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCOFree Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 1.37% of Onconetix as of its most recent filing with the SEC. Hedge funds and other institutional investors own 23.89% of the company’s stock.

Onconetix Company Profile

(Get Free Report)

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.

Recommended Stories

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.